Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- None.
- None.
Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130180434/en/
Media Contact
Will Zasadny
Inizio Evoke Comms
(619) 961-8848
will.zasadny@inizioevoke.com
media@sprucebio.com
Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com
Source: Spruce Biosciences, Inc.
FAQ
When will Spruce Biosciences present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?
What is the focus of Spruce Biosciences?
Where can the live webcast be accessed?
How long will the archived copy of the webcast be available?
